Abstract:Vascular endothelial growth factor (VEGF), along with its receptor tyrosine kinases VEGFR-2 or kinase insert domain receptor (KDR), are targets for development of novel anticancer agents. Accurately predicting the structural characteristics of the target and chemical features of ligands can greatly reduce the cost and shorten the cycle of designing selective KDR inhibitors with desired activity. In this study, a docking strategy and three dimensional holographic vector of atomic interaction field (3D-HoVAIF) were applied in QSAR analysis of KDR inhibitors. The optimal model was constructed by using stepwise regression combined with partial least squares regression (SMR-PLS). Integrating the results of QSAR analysis, ADMET, pharmacophore modeling and a reverse screening strategy, eight derivatives were identified as potential KDR inhibitors. Then molecular dynamics (MD) simulations and free energy calculations were employed to explore the detailed binding process, so as to compare the potential binding modes of inhibitors with different activities. By analyzing the key residues in the binding site, it was found that different KDR–ligand complexes had similar binding modes. The predicted binding affinities were highly correlated with the experimental biological activity. Free energy analysis indicated that van der Waals interactions provided the major driving force for the binding process. Furthermore, key residues, such as Leu840, Val848, Ala866, Lys868, Leu889, Val899, Thr916, Phe918, Cys919, Leu1035, Cys1045, Asp1046, and Phe1047 played a vital role in forming hydrogen bonds, salt bridges, and hydrophobic interactions with the conformation of KDR. The above results will help design more efficient KDR inhibitors.

Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors

Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

Pharmacophore Identification, Docking and "in Silico" Screening for Novel Cdk1 Inhibitors

Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on It for Novel Inhibitors.

Discovery of vascular endothelial growth factor receptor tyrosine kinase inhibitors by quantitative structure–activity relationships, molecular dynamics simulation and free energy calculation

Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.

De novo design of N -(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction

Pharmacophore modeling and hybrid virtual screening for the discovery of novel IκB kinase 2 (IKK2) inhibitors.

Pharmacophore Models Generation by Catalyst and Phase Consensus-Based Virtual Screening Protocol Against PI3Kα Inhibitors

Structure-based and Shape-Complemented Pharmacophore Modeling for the Discovery of Novel Checkpoint Kinase 1 Inhibitors

Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it.

Combination Of Pharmacophore Model Development And Binding Mode Analyses: Identification Of Ligand Features Essential For I Kappa B Kinase-Beta (Ikk Beta) Inhibitors And Virtual Screening Based On It

Pharmacophore Modeling and Virtual Screening to Identify Potential RET Kinase Inhibitors.

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

In Silico Approaches Using Pharmacophore Model Combined with Molecular Docking for Discovery of Novel ULK1 Inhibitors.

Establishment and Application of High Throughput Screening Model for Kinase Insert Domain Receptor

Pharmacophore Modeling Study Based on Known Spleen Tyrosine Kinase Inhibitors Together with Virtual Screening for Identifying Novel Inhibitors.

Pharmacophore Modeling and Virtual Screening Studies of Checkpoint Kinase 1 Inhibitors.

Pharmacophore Modeling, Virtual Screening, and Molecular Docking Studies for Discovery of Novel Akt2 Inhibitors.

Combined Pharmacophore Models As Virtual Screening Protocol Against BRD4(1) Inhibitor